Trial · NCT07913321
Efficacy and Safety of Oral Ivermectin for Genital Warts
NCT07913321, Not applicable, Not yet recruiting, University of Health Sciences Lahore
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Efficacy and Safety of Oral Ivermectin for Genital Warts. Trials, record NCT07913321. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913321
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Oral Ivermectin for Genital Warts
- NCT number
- NCT07913321
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 90 participants, estimated
- Lead sponsor
- University of Health Sciences Lahore
- Conditions
- Genital Warts
- Interventions
- Ivermectin
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Wart Clearance | 8 weeks after treatment initiation | Proportion of participants achieving complete clearance of all clinically visible genital warts following oral ivermectin treatment. Complete response is defined as 100% clearance of all clinically visible genital warts compared with baseline. |
| Secondary | Partial Wart Response | 8 weeks after treatment initiation | Proportion of participants achieving at least a 50% reduction in the total number of genital warts and/or the measured size of target lesions compared with baseline. |
| Secondary | Reduction in Wart Number | Baseline, weeks 2, 4, and 8 after treatment initiation | Change in the total number of clinically visible genital warts from baseline, assessed by direct lesion count at follow-up visits. |
| Secondary | Reduction in Wart Size | Baseline, weeks 2, 4, and 8 after treatment initiation | Change in the size of target genital warts from baseline, measured in millimetres using the largest diameter of the lesions. |
| Secondary | Development of New Lesions | Weeks 2, 4, and 8 after treatment initiation | Proportion of participants developing new genital wart lesions during the treatment and follow-up period, as documented during clinical assessments. |
| Secondary | Recurrence | Through week 8 | Proportion of participants experiencing recurrence of genital warts during the study period, as documented in the study proforma. |
| Secondary | Adverse Effects | Weeks 2, 4, and 8 after treatment initiation | Proportion of participants experiencing adverse effects following oral ivermectin administration, including gastrointestinal symptoms, dizziness, headache, skin rash, and pruritus. The type, frequency, and severity of adverse effects will be recorded. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913321
GET https://conductscience.org/api/trials/v1/NCT07913321/registered